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Summary
β-Lactams (β-Ls) represent the most frequent cause of adverse drug reactions (ADRs) due to immunological mechanisms. The 
diagnostic platform is actually based on in vivo assays, whereas in vitro assays do not seem to appropriately answer the requirements 
of clinical practice and they are mainly field of research or still matter of debate. Both specific IgE determination and lymphocyte 
transformation test (LTT) exhibit modest (if not low) sensitivity whereas flow-cytometric basophil activation test is still under 
investigation and limited to immediate reactions. Although short-term T-cell lines (TCLs) have only been used so far to characterize 
the immunological mechanisms of ADRs,  taking advantage from a large number of selected patients with history of β-Lactam 
sensitization we demonstrate here that hapten-specific TCLs can be induced from the peripheral blood of high proportions of ADR+ 
patients independently of circulating  IgE and LTT, type (immediate vs delayed) or extension (local vs systemic) of the reaction. We 
also show that wide cross-reactivity between β-L-haptens is exhibited by short-term T-cell lines and detection of specificity can 
be performed independently of processing-dependent presentation. On the basis of these results, IgE detection, LTT and hapten-
specific TCL induction altogether exhibit high specificity (95.5%) and sensitivity (80.5%) thus significantly improving the diagnostic 
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Introduction
In most epidemiological studies antibiotics are commonly 
involved in drug allergy. In particular, β-Lactams (β-Ls) 
are the most frequent cause of adverse reactions (ADRs) 
mediated by immunological defined mechanisms and, 
along with this, amoxicillin has now replaced benzylpeni-
cillin as causative hapten due to its widespread use  1 2. 
According to the time interval between drug administra-
tion and the onset of symptoms, ADRs are classified as 
immediate- (within 1 hr) or nonimmediate-(or delayed-) 
type reactions (from 1 hr on) 3 4 and clinically character-
ized by skin-limited pictures (urticaria/angioedema and 
rashes, respectively) or systemic involvement (anaphy-
laxis and DRESS/AGEP/SJS, respectively) or various 
combination of them 3. Traditionally, immediate ADRs are 
mediated by specific IgE whereas delayed reactions are 
more heterogeneous 3 5 6 even if the role of T cells (type 
IV hypersensitivity), recently categorized in at least four 
different phenotypes, is well-stated in most of them 3 5 7. 
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In the present study, using a large number of selected 
patients with history of β-Lactam sensitization, we 
demonstrate how the induction of hapten-specific T 
cell lines with their wide cross-reactivity between β-L-
haptens significantly improves the diagnostic perfor-
mance of the available in vitro tests (IgE detection and 
LTT) independently of the type (immediate vs. delayed) 




A total number of 204 consecutive patients who were 
referred to the Immunoallergology Departments of 
Azienda Ospedaliero-Universitaria Careggi and Ospeda-
le Nuovo San Giovanni di Dio in Florence with a history 
of ADRs to β-Ls, were enrolled in the study. All the 
patients were evaluated for the atopic phenotype on the 
basis of history, clinical symptoms and skin prick tests 
(SPT) for common allergens. ADRs were categorized as 
immediate (within 1 h from the exposure with clinical 
symptoms characterized by orticaria and/or angioede-
ma or anaphylaxis-related symptoms) or delayed (from 
1h to 14 days from the exposure with clinical symptoms 
characterized by cutaneous rash or other skin involve-
ment or systemic involvement as DRESS, AGEP or SJS/
TEN) as stated by ENDA 1.
One hundred thirty five patients showed immediate 
ADRs whereas 69 delayed ADRs to β-Ls (ADR+ donors). 
A group of 88 subjects with negative history of adverse 
reactions (53 atopic and 35 non-atopic) was also enrol-
led (ADR- donors) with reported tolerance to β-Ls in the 
last year and negative skin testing. Blood samples were 
obtained from informed ADR+ and ADR- subjects in ac-
cordance with the ethical standards of the responsible 
regional committee on human experimentation. 
β-L hypersensitivity was proven by history and the 
presence of serum specific IgE. All the ADR+ patients 
were checked within one year from the reaction, with 
the exception of 3 of them reporting ADRs more than 
10 years before.
The majority (n = 162) of ADR+ patients developed re-
action to amoxicillin (Ax), 12 to penicillin (Pe) and 30 to 
ampicillin (Am). Few patients had positive history of reac-
However, the role of T cells is not limited to non-immedi-
ate reactions as cooperation between helper T cell able 
to produce TH2 cytokines and antibody-forming B cells is 
necessary for IgE-switch 8. 
Besides the improvements in understanding the mo-
lecular mechanisms of ADRs, the diagnostic manage-
ment still offers difficulties in clinical practice  4   9  10. A 
throughout history is necessary to indentify the culprit 
drug together with timing of clinical manifestations 
whereas in vivo tests (skin prick, intradermal and patch 
tests) still represent the basic platform for diagnosis even 
if potentially risky in patients with severe anaphylaxis 9-11 
and not adequately sensitive in non-immediate reac-
tions 10 12. The in vitro assays are still field of research and 
matter of debate. The detection of specific IgE for years 
represented the way to ascertain hapten-sensitization 
with substantial limitation to immediate reactions 10 13 14, 
major concerns about sensitivity and the influence of total 
serum IgE levels 15. In immediate reactions, the possible 
diagnostic extension to flow-cytometric basophil activa-
tion test is under investigation 16. In cell-mediated reac-
tions, the activation of drug-specific circulating T cells 
has been investigated by means of proliferation assay 
(lymphocyte transformation test, LTT) 17-20 with the use of 
dendritic cells to potentiate hapten-recognition 21 or CD69 
expression by drug-activated T cells in cytofluorometric 
analysis 22 as attempts to improve sensitivity and detect 
the few circulating memory cells by-passing radionuclide 
use, respectively. Actually, the frequency of circulating 
drug-specific T cells has been calculated by few Au-
thors 23 24 and it may be higher than expected and ranging 
from 1/1,250 to 1/10,000, thus not far from the ordinary 
antigen-specific T cells 25 26. These results are at variance 
with the low sensitivity of LTT (reported between 40 and 
70%) 17 27 suggesting a low frequency of circulating pre-
cursors eventually influenced by the type of hapten and/
or reactions (immediate versus delayed) and the cut-off 
points of mitogenic index 17 27. 
Short-term T-cell lines (TCLs) from the peripheral blood 
of patients with drug sensitivity were actually used to 
better characterize the immunological mechanisms of 
adverse reactions  6  28  29 whereas their application for 
diagnostic purposes has never been envisaged though 
it may represent a tool to expand hapten-responsive 
T cells.
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β-L-Specific ige 
Detection of serum β-L-specific immunoglobulin E an-
tibodies was based on the ImmunoCAP System FEIA 
(Thermo Fisher Scientific Inc.) towards haptens c1 (peni-
cilloyl G), c5 (ampicilloyl) and c6 (amoxicilloyl) according 
to the manufacturer’s instructions with a cut-off value of 
positivity 0.10 KUA/L. 
Lymphocyte tranSformation teSt (Ltt)
PBMC from ADR+ and ADR- subjects were isolated by 
Ficoll-Hypaque (Pharmacia) density gradient followed by 
two washings with PBS pH 7.2. 1x106/ml cells were cul-
tured in triplicate in U-round bottomed well plates (Nunc) 
tions to two different β-Ls: 6 patients to Ax and Am, 3 to 
Ax and Pe and 1 to Am and Pe. 
Table  I (A and B) summarizes the characteristics of the 
donors used in the study.
reagentS
The medium used throughout was RPMI 1640 (VLE, 
Biochrom AG) supplemented with 2 mM endotoxin-free 
L-glutamine, 1% non-essential aminoacids, 1% so-
dium pyruvate (Sigma Chemical Co) and 2x10-5 M 2-ME 
(Merck) (complete medium). Amoxicillin, Ampicillin and 
Penicillin were provided from Sigma. rIL-2 was purchased 
by Novartis (Proleukin®). 
table ia. Characteristics of the study population.
Subjects 
ADR + ADR- 
N° 204 88
Age (range, yrs) 18-69 18-61
Gender (F/M) 98/106 45/43
Atopy (%) 54 51
Total serum IgE (mean ± SE, KU/L) 164±23 152±36
table ib. Clinical features of the patients with positive history of adverse drug reaction.
Patients with history of ADR 









Amoxicillin 162 (79.4) 112 (83) 50 (72)
Ampicillin 30 (14.7) 14 (10) 17 (25)
Penicillin 12 (5.9) 9 (7) 2 (3)
Time interval since ADR 





Detection of β-L-Specific ige anD memory t ceLLS 
in aDr+ patientS with immeDiate- or DeLayeD-type 
reactionS
We firstly evaluated serum IgE and memory T cells by 
means of LTT assay specific for the culprit hapten (and the 
other related β-Ls) in ADR+ patients and ADR- controls.
Fourty six out of 194 (23,7%) ADR+ patients showed 
detectable IgE levels (> 0.1 KUA/L) towards β-Ls with 
expected statistically significant prevalence in patients 
with history of immediate type of reactions (38/126, 
30,1%) compared to 8/68 (11,7%) patients with de-
layed reactions (p < 0,0001), whereas only 3/86 ADR- 
subjects (3.5%, p  <  0.0001) showed IgE levels above 
the cut-off limit (Tab.  II). Seventy out of 194 (36.1 %) 
patients (56 with immediate- and 14 with delayed-type 
reactions) showed β-Ls-specific IgE towards one or 
more haptens, and, possibly, irrespectively of the culprit 
drug (data not shown). On the whole, the IgE determina-
tion in the serum showed high specificity (95.9%), low 
sensitivity (40.2%) (Tab. III). 
We then assayed lymphocyte transformation test (LTT) 
by stimulating PBMC of 204 ADR+ patients using three 
different concentrations of each hapten. Seventy-seven 
out of 204 (37.7%) ADR+ patients showed positive LTT 
response to the culprit drug (58 to Ax, 13 to Am and 6 
to Pe). Among them 47/135 (34.8%) patients had history 
of immediate- and 30/69 (43.5%) of delayed-type reac-
tions, the difference between the two groups being not 
significant. Moreover, 54/77 LTT+ ADR+ patients (70.1%) 
in complete medium plus 5% heat-inactivated autologous 
serum in 0.2 ml final volume for 5 days in presence of 
three doses of the haptens (2.5-0.5-0.1 mg/ml). After 16 
h pulsing with 0.5  mCi 3HTdR per well (Perkin Elmer), 
cultures were harvested and radionuclide uptake mea-
sured by scintillation counting. T-cell proliferation were 
considered as specific when mitogenic index in response 
of a single dose of hapten was ≥  5 or above 3 in two 
consecutive doses.
generation of Short-term haptenS-Specific  
t-ceLL LineS anD cLoneS
Short-term drug-specific CD4+ T-cell lines were genera-
ted as previously described 29. Briefly, PBMC from ADR+ 
and ADR- subjects were stimulated with haptens (Ax, Am 
or Pe, all at 0.5 mg/ml) for six days and activated T cells 
were expanded for further 8 days by the addition of rIL-2 
(25 U/ml) every three days. 
T cell clones were generated from T cell lines derived 
from PBMC of ADR+ and ADR- subjects and the clonal 
efficiency evaluated as previously reported  29  30. The 
specificity of short-term T-cell lines and T cell clones was 
assessed as already described  29. T-cell lines or clones 
were considered as specific when mitogenic index of a 
single dose was ≥ 3. 
StatiSticaL anaLySiS
Sensitivity and specificity data were obtained from the 
cross-tabulation of positive and negative test results in 
the whole sample, and in subgroups of variables of inte-
rest. Statistical analysis of the results was performed by 
Student’s t-test and Mann Whitney test; a p value < 0.05 
was considered as significant.
table ii. Assessment of β-L-specifc IgE levels to the culprit drug in the study population.
History Type of reaction N° of patients
Patients with 
β-L-specific IgE (%)
> 0.1 KU/L < 0.1 KU/L
ADR+ 194 46 (23.7)a 148 (76.3)
Immediate-type 126 38 (30.1)b 88 (69.9)
Delayed-type 68 8 (11.6)c 60 (88.3)
ADR- 86 3 (3.5)d 83 (96.5)
p values: a vs. d < 0.0001, b vs. c < 0.0001
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we then used an in vitro amplification system generat-
ing short-term T-cell lines (TCLs) from PBMC of 128 
selected ADR+ patients (78 with immediate and 50 with 
delayed-type reaction) stimulated with β-L-haptens (Ax, 
Am and Pe) followed by expansion with rIL-2. To assess 
hapten-specificity of TCLs, T cell blasts were stimu-
lated in the presence of irradiated autologous antigen-
presenting cells plus hapten (processing-dependent 
presentation) when PBMNC were available, or hapten 
alone (antigen processing-independent or T-T presenta-
tion). In 43 ADR+ patients the specificity of 118 TCLs 
could be assessed by both systems and compared with 
the finding that not only antigen-processing dependent 
and T-T presentation were strictly and significantly cor-
related (p = 0.0005) (data not shown) but also mitogenic 
indexes (MI) (p < 0.0001, Fig. 1A) as demonstrated by 
Fisher’s exact test. To provide further evidence that 
memory T cells equally well recognized drug haptens 
after processing-dependent or independent fashion, 85 
T-cell clones specific for Pe derived from a Pe-specific 
TCL of one ADR+ patient (FF) were also studied confirm-
ing a strict and significant correlation between the two 
kind of responses (p < 0.001) (Fig. 1B). These findings 
suggested that, at least for diagnostic purposes, the 
methods to detect TCL specificity offer similar results 
and can be equally used. 
also exhibited T cell recognition towards additional one 
(32 patients) or two (22) β-Ls (Tab.  IVB). Additional 13 
patients (9 with immediate- and 4 with delayed-type 
reactions) showed LTT positivity to one (12) or two (1) 
haptens different from the culprit drug (data not shown). 
On the other hand, 9 out of 88 (10.2%) ADR- donors 
exhibited a positive LTT when the maximal concentration 
of Ax was used, whereas none of them exhibited positive 
T-cell response towards Pe or Am (Tab. IVA). On the basis 
of the results, LTT exhibited good specificity (91.2%) 
but low sensitivity (42.7%) (Tab.  III) whereas when both 
IgE detection and LTT were performed together, a slight 
increase in sensitivity (57.6%) was observed (Tab.  III). 
When LTT and IgE levels in the same patients were 
compared, no correlation between the two assays was 
seen indipendently of the immediate (Fig. 1A) or delayed 
(Fig. 1B) type of the reactions or the kind of hapten (data 
not shown) suggesting that, at least in some patients, 
circulating β-L-specific memory T cells may be too few 
to be detected by ordinary LTT assay, even though IgE are 
still detectable in the serum. 
hapten-Specificity of β-L-Specific t-ceLL LineS can 
be DetecteD by either proceSSing-DepenDent  
or inDepenDent preSentation
In the view that the proportion of circulating β-L-specific 
T cells may be too low to be detected by the use of LTT, 
table iii. Diagnostic performance of IgE detection, LTT and TCL-induction in patients with history of ADRs to β-Ls.
Assay (s) Performance Type of adverse reaction
Immediate Delayed Any
IgE detection
Specificity 95.0 83.2 95.9
Sensitivity 54.6 60.5 40.2
LTT
Specificity 86.5 80.0 91.2
Sensitivity 51.9 70.5 42.7
IgE detection + LTT
Specificity 89.2 80.7 92.5
Sensitivity 69.7 76.8 57.6
IgE detection + LTT+ TCL induction
Specificity 92.5 87.5 95.5
Sensitivity 85.5 93.2 80.5
L. Filì et al.
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β-Ls independently of the drug used for the induction. 
The proportion of cross-reacting TCLs was indeed simi-
larly distributed in patients with immediate or delayed 
reactions (Fig. 2A). Further, and more interestingly, we 
could derive hapten-specific TCLs in 21 out of 36 pa-
tients (58.3%) with history of immediate-type adverse 
reactions but undetectable serum IgE and negative LTT 
(IgE- LTT-) with single specificity in 8 patients, recog-
nition of two haptens in 8 and broad reactivity in 5. 
Analogously, from 19 IgE-LTT- patients with delayed re-
actions, hapten-specific TCLs could be generated from 
13 (68.4%) (single positivity in 7 patients, recognition of 
two haptens in 4 and broad reactivity in 2) (Tab. V). Of 
β-L-Specific t-ceLL LineS can be inDuceD 
in high proportionS of aDr+ patientS inDepenDentLy 
of circuLating ige anD Ltt
Hapten-specific TCLs derived from 128 ADR+ patients 
were then studied in relation to the time interval be-
tween drug intake and clinical symptoms. Similar num-
bers of specific TCLs could be derived without any sig-
nificant difference when immediate or delayed reactions 
were considered (Ax 34/78 vs. 24/50 [43.5% vs. 48%]; 
Am 27/78 vs. 16/50 [34.6% vs. 32%]; Pe 36/78 vs. 
23/50 [46.1% vs. 46%], respectively) (data not shown). 
As shown in Figure 2, a high degree of cross-reactivity 
between the three haptens was observed and a consid-
erable proportion of TCLs equally well recognized all the 
figure 1. Specificity of T cell lines and clones evaluated by TT- or MNC-presentation of β-Lactams. 
A: correlation between the mitogenic indexes of the proliferative response of 118 β-L-specific T cell lines after TT- or autologous MNC-presen-
tation of haptens. The protocol to derive T cell lines and the methods to assess their specificity are described in materials and methods. B: cor-
relation between the mitogenic indexes of the proliferative response of 85 Pe-specific T cell clones after TT- or autologous MNC-presentation of 
haptens. The protocol to obtain β-L-specific T cell clones and the methods to assess their specificity are described in materials and methods.
table iVa. Assessment of β-L-specifc T-cell proliferation to the culprit drug in the study population.
History Type of reaction N° of patients Patients with positive LTT to hapten (%)
Any Ax Am Pe
ADR+ All 204 77 (37.7) 58 13 6
Immediate 135 47 (34.8)a
Delayed 69 30 (43.5)b
ADR- 88 9 (10.2) 9 0 0
p value: a vs. b NS
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crease in specificity (95.5%) and a dramatic ameliora-
tion of sensitivity (80.5%) was observed (Tab. III). 
Discussion
The diagnosis of drug hypersensitivity is a major chal-
lenge in clinical practice as skin tests may result in nega-
note, TCLs derived from IgE-LTT- patients (irrespective 
of immediate or delayed reactions), also exhibited a high 
degree of crossreactivity to the three different β-Ls, 
even if at a lower extent than in IgE (+/-) LTT+ patients 
(Fig. 2B). On the basis of these results, when the three 
different assays (IgE detection, LTT and hapten-specific 
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figure 2. Cross-reactivity of T cell lines derived from patients exhibiting positive or negative LTT. Proportions of T cell lines specific for Ax, Am, 
and Pe derived from PBMNC of ADR+ patients showing LTT positive with or without IgE (IgE+/-) (panel A) and LTT negative (panel B) assays. The 
latter group of ADR+ patients showed also no detectable anti-hapten IgE Abs in the serum (IgE-). Each T cell line was generated against one β-L 
(Ax: black columns, Am: grey columns, Pe: white columns) and also assessed with the other two, as described in materials and methods. The 
percentages of specific and cross-reacting T cell lines are reported. 
table iVb. Assessment of β-L-specific T-cell recognition towards the different haptens in patients with history of ADRs.





One hapten 28 (20.7) < 0.001 7 (10.1)
Two haptens 15 (11.1) < 0.02 17 (24.6)
Three haptens 12 (8.8) NS 10 (14.5)
Amoxicillin 46 (34.1) NS 33 (47.8)
Ampicillin 27 (20.0) <0.02 25 (36.2)
Penicillin 22 (16.3) NS 13 (18.8)
L. Filì et al.
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Our study population was also further in vitro screened 
by means of lymphocyte transformation test (LTT). Sev-
eral reports calculated sensitivity and specificity of this 
test with concerns about the size of the population, the 
wide range of sensitizing drugs and clinical manifesta-
tions  19  27. In the study of Luque et al.  17 assessing a 
robust number of selected patients sensitivity was 62% 
and specificity 92.8%. Our results confirmed specificity 
value but were at variance about overall sensitivity. In 
addition, in our hands, sensitivity was higher in delayed-
type than immediate reactions. These differences could 
be partially due to the cut-off limits of proliferation as 
we adopted as positive MI (as mean MI from triplicate 
cultures) >  5 in response to a single concentration of 
the drug and > 3 in at least two consecutive concentra-
tions in order to maintain optimal specificity. Despite 
these restricted limits, it was not clear why positive pro-
liferative responses could be also observed in a small 
number of healthy subjects despite drug tolerance and 
negative skin prick tests. Similar results have already 
been observed by others  17  27. It cannot be excluded 
that previous exposures of normal donors to β-Ls might 
have been responsible of the development of few non-
pathogenic specific memory T cells. A second explana-
tion could reside into in vitro culture conditions as T-cell 
response only occurred at the highest concentration of 
amoxicillin. It is thus possible that these conditions, not 
normally occurring in vivo, could be able to activate T 
cells in vitro. A third possibility could be represented 
by the well-known instability of amoxicillin in aqueous 
solutions with the production of several degradation 
products including non-allergenic haptens  32  33. Even 
if at-the-moment-prepared solutions of β-Ls from 
powder stocks were used throughout the study, limited 
amounts of haptens different from the entire molecule 
could be assessed by NMR spectral studies (Filì L and 
tive responses, challenge tests may be risky in systemic 
reactions and contraindicated in severe reactions and 
available in vitro methods, though safe, are usually con-
sidered as complementary because of concerns about 
their sensitivity 4 7 13. 
In this study, using a large number of patients with 
selective history of adverse reactions to β-Lactams we 
analyzed specificity and sensitivity of IgE detection and 
LTT and showed that induction of hapten-specific T cell 
lines significantly improves the diagnostic performances 
thus representing an attractive method to enlarge in vitro 
diagnostic tools. 
We first investigated β-L-specific IgE levels towards the 
commercially available penicilloyl G and V, ampicilloyl 
and amoxicilloyl in all the patients. The persistence of 
circulating IgE in the absence of the stimulating agent 
(in this case, hapten) is still a challenge even if long-
living plasma cells, at least specific for conventional 
antigens, are shown to accumulate in the bone mar-
row  31. However, β-L-specific levels are usually lower 
than allergen-specific IgE, reduce progressively over the 
time 10 13 and are deeply influenced by total IgE levels 15. 
For this reason, patients of our study were selected as 
referring adverse reactions within one month to one 
year time-interval from the acute manifestations and 
showing less than 250 KU/L total IgE. IgE detection ex-
hibited a low overall sensitivity as less than one fourth 
of patients showed circulating detectable levels of IgE 
to the culprit β-L with expected statistically significant 
prevalence in immediate- type of reactions. However, 
as a confirm of the high degree of cross-reactivity be-
tween β-Lactams, the percentage of patients exhibit-
ing detectable levels of drug-specific IgE consistently 
increased to about one third when it was not limited to 
the culprit drug but broadly considered towards any of 
the haptens. 
table V. β-L-specificity of T cell lines derived from patients with history of ADRs but negative to both LTT and IgE.
Type of reaction
N° of patients LTT - IgE (%) N° of T cell lines reactive to








Immediate 36 21 (58.3) 8 8 5
Delayed 19 13 (68.4) 7 4 2
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tool also to ascertain old drug sensitizations and could 
be restricted to those patients with negative standard in 
vitro tests (circulating IgE and/or LTT). 
It is known that haptens can elicit activation of specific 
T cell after processing and presentation by professional 
APCs as linked to serum proteins or after direct binding to 
MHC antigens 35. In our study, we screened a high number 
of drug-induced T cell lines and found that β-L-specificity 
could be either assessed under MHC-restricted condi-
tions when autologous MNC as antigen-presenting cells 
were available or, with comparable efficiency, directly 
adding the single haptens into the culture (so called T-T 
presentation). The correlation between the two systems 
was confirmed at clonal level. This finding obviously 
represents a clear advantage as allowing a simple scree-
ning system not requiring additional blood sampling from 
the patients. 
On the whole, even though in vivo skin tests are accurate 
methods to assess β-L sensitization, the results of our 
exclusively culture-focused study demonstrate that ex-
pansion of memory cells through the induction of hapten-
specific T cell lines significantly improves the accuracy 
of the standard in vitro tests and enlarge the diagnostic 
tools in the sensitization to β-Lactams. 
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